Across TCGA pan-cancer cohorts, RPS18 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated RPS18 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher RPS18 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RPS18 expression acts as an unfavorable survival marker.
LUSC are the cancer types where RPS18 Mutation most reproducibly stratifies survival.